Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis.

Mathilde LeclercqPascal SèveLucie BiardMathieu VautierGeorgina MaaloufGaëlle LerouxFanny DomontAdélaïde ToutéeChristine FardeauThomas Sales de GauzySara TouhamiLaurent KodjikianPatrice CacoubBahram BodaghiDavid SaadounAnne-Claire Desbois

Published in: The British journal of ophthalmology (2024)

In non-anterior sarcoidosis-associated uveitis, MTX seems to be more efficient compared with AZA and MMF and with an acceptable safety profile.

Keyphrases

juvenile idiopathic arthritis
ankylosing spondylitis
rheumatoid arthritis
rheumatoid arthritis patients
disease activity
low dose
systemic lupus erythematosus
combination therapy